三阴性乳腺癌 (TNBC) 约占所有乳腺癌病例的 10-20%，且预后不良。直到最近，TNBC 的治疗选择还仅限于化疗。一种新的成功的全身治疗方法是使用免疫检查点抑制剂进行免疫治疗，但需要新的肿瘤特异性生物标志物来改善患者的治疗效果。在 TNBC 模型的大多数临床前研究中，大麻素显示出抗肿瘤活性，并且似乎不会对化疗产生不良影响。需要临床数据来评估对人类的有效性和安全性。重要的是，内源性大麻素系统与免疫系统和免疫抑制有关。因此，大麻素受体可能是免疫检查点抑制剂治疗的潜在生物标志物或逆转免疫治疗耐药性的新机制。在本文中，我们概述了有关大麻素如何影响 TNBC 标准治疗的当前可用信息。版权所有 © 2024 Dobovišek、Borštnar、Debeljak 和 Kranjc Brezar。

Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC.Copyright © 2024 Dobovišek, Borštnar, Debeljak and Kranjc Brezar.